L. Korkmaz Et Al. , "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?," American Journal of Perinatology , vol.39, no.2, pp.204-215, 2022
Korkmaz, L. Et Al. 2022. Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?. American Journal of Perinatology , vol.39, no.2 , 204-215.
Korkmaz, L., Ozdemir, A., PAMUKÇU, Ö., GÜNEŞ, T., & ÖZTÜRK, A., (2022). Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?. American Journal of Perinatology , vol.39, no.2, 204-215.
Korkmaz, Levent Et Al. "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?," American Journal of Perinatology , vol.39, no.2, 204-215, 2022
Korkmaz, Levent Et Al. "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?." American Journal of Perinatology , vol.39, no.2, pp.204-215, 2022
Korkmaz, L. Et Al. (2022) . "Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?." American Journal of Perinatology , vol.39, no.2, pp.204-215.
@article{article, author={Levent Korkmaz Et Al. }, title={Which Inotropic Drug, Dobutamine or Milrinone, Is Clinically More Effective in the Treatment of Postligation Cardiac Syndrome in Preterm Infants?}, journal={American Journal of Perinatology}, year=2022, pages={204-215} }